98%
921
2 minutes
20
Background: The relationship between cumulative low-density lipoprotein cholesterol (LDL-C) exposure and progression of atherosclerosis remains uncertain.
Objective: The aim of this study was to determine the relationship between cumulative LDL-C level and flow-mediated vasodilation (FMD), nitroglycerine-induced vasodilation (NID) and the presence of plaque in the common carotid artery (CCA).
Methods: This was a cross-sectional study. We measured FMD in 8208 subjects, NID in 1822 subjects, and CCA plaque in 591 subjects who were not taking lipid-lowering drugs. The subjects were divided into four groups based on cumulative LDL-C exposure: <4000 mg·year/dL, 4000-4999 mg·year/dL, 5000-5999 mg·year/dL, and ≥6000 mg·year/dL.
Results: The odds ratio of the lower quartile of FMD in the cholesterol-year-score <4000 mg·year/dL group was significantly higher than the odds ratios in the other groups. The odds ratio of the lower quartile of NID in the <4000 mg·year/dL group was significantly higher than the odds ratios in the 5000-5999 mg·year/dL and ≥6000 mg·year/dL groups. The odds ratio of the prevalence of CCA plaque in the <4000 mg·year/dL group was significantly higher than that in the ≥6000 mg·year/dL group.
Conclusions: Endothelial dysfunction occurred from cumulative LDL-C exposure of 4000 mg·year/dL, vascular smooth muscle dysfunction occurred from cumulative LDL-C exposure of 5000 mg·year/dL, and prevalence of CCA plaque occurred from cumulative LDL-C exposure of 6000 mg·year/dL. CLINICAL TRIAL REGISTRY INFORMATION: http://www.umin.ac.jp (UMIN000012950, UMIN000012951, and UMIN000012952, UMIN000003409).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jacl.2023.12.006 | DOI Listing |
Front Pharmacol
August 2025
Department of Hepatobiliary Surgery, Zigong Fourth People's Hospital, Zigong, China.
Introduction: We conducted a network meta-analysis (NMA) to compare the efficacy (primarily assessed by low-density lipoprotein cholesterol (LDL-C) reduction and cardiovascular event (CVE) incidence) and safety (total adverse events (AEs), neurocognitive events (NCEs), injection site reactions, infections, and all-cause mortality (ACM)) of different Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors placebo in the general population and solid organ transplant (SOT) recipients.
Materials And Methods: A total of 16 randomized controlled trials (RCTs) involving 79,615 patients were included. Cochrane risk of bias assessment tool evaluated the literature quality.
J Clin Lipidol
August 2025
The Research Unit of Evidence Synthesis (TRUES), Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand (Dr. Dhippayom); Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA (Dr. Dhippayom).
Background: Statin intolerance presents a considerable challenge in managing patients at risk for cardiovascular diseases, as it limits patients' access to standard lipid-lowering therapies.
Objective: This study aims to compare the efficacy and safety of various nonstatin lipid-lowering therapies in patients who are intolerant to statins.
Methods: We searched PubMed, Embase, CENTRAL, and EBSCO open dissertations through September 2023 for randomized controlled trials in statin-intolerant patients comparing nonstatin lipid-lowering agents.
Ann Med Surg (Lond)
September 2025
College of Medicine, University of Baghdad, Baghdad, Iraq.
Background: Nonalcoholic fatty liver disease (NAFLD) is a global health concern associated with dyslipidemia, obesity, and type 2 diabetes mellitus (T2DM), necessitating effective therapeutic strategies. Sodium-glucose transporter 2 (SGLT-2) inhibitors have shown promise in improving metabolic parameters, but their comparative efficacy in NAFLD remains unclear.
Methods: We systematically searched PubMed, Cochrane Library, Scopus, and Embase for randomized controlled trials (RCTs) up to 31 December 2024, involving NAFLD patients treated with SGLT-2 inhibitors versus placebo or standard treatments.
EClinicalMedicine
September 2025
Gastroenterology, Duke University Medical Center, Durham, NC, USA.
Background: The hepatoprotective effects of statins in chronic liver diseases are well-documented; however, variation by age, sex, and formulation remains unclear. The optimal regimen for cirrhosis prevention has yet to be defined. We aimed to address this knowledge gap.
View Article and Find Full Text PDFBMC Immunol
September 2025
Department of Cardiology, The Affiliated Hospital of Chengde Medical University, Chengde, 067000, China.
Introduction: An accurate assessment of prognostic risk is widely recognized to be important in improving the survival of patients with acute coronary syndrome (ACS). This study aimed to investigate the roles of neutrophil-to-lymphocyte * platelet (NLPR) and neutrophil-lymphocyte (NLR) ratios with high- and (HDL-C) and low-density lipoprotein cholesterol (LDL-C) levels in predicting the risk of major adverse cardiovascular events (MACEs) in patients with ACS undergoing percutaneous coronary intervention (PCI).
Results: Overall, 1,263 patients with ACS undergoing PCI between January 2016 and December 2018 were consecutively enrolled.